Is Bio Path Holdings Inc (BPTH) Stock About to Get Hot Friday?

Bio Path Holdings Inc (BPTH) stock is up 16.44% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Bio Path Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BPTH!

See Full BPTH Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With BPTH Stock Today?

Bio Path Holdings Inc (BPTH) stock has gained 4.29% while the S&P 500 is lower by -0.65% as of 12:27 PM on Friday, Dec 2. BPTH has gained $0.07 from the previous closing price of $1.63 on volume of 26,484 shares. Over the past year the S&P 500 is down -10.26% while BPTH is lower by -59.72%. BPTH lost -$1.96 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Bio Path Holdings Inc click here.

More About Bio Path Holdings Inc

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Click Here to get the full Stock Report for Bio Path Holdings Inc stock.